ES2179040T3 - Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b. - Google Patents

Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.

Info

Publication number
ES2179040T3
ES2179040T3 ES92906520T ES92906520T ES2179040T3 ES 2179040 T3 ES2179040 T3 ES 2179040T3 ES 92906520 T ES92906520 T ES 92906520T ES 92906520 T ES92906520 T ES 92906520T ES 2179040 T3 ES2179040 T3 ES 2179040T3
Authority
ES
Spain
Prior art keywords
hepatitis
treatment
thiacitidine
desoxi
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92906520T
Other languages
English (en)
Inventor
Dennis C Liotta
Raymond F Schinazi
Woo-Baeg Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919104741A external-priority patent/GB9104741D0/en
Priority claimed from GB919109505A external-priority patent/GB9109505D0/en
Application filed by Emory University filed Critical Emory University
Application granted granted Critical
Publication of ES2179040T3 publication Critical patent/ES2179040T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE DESCUBRE EL USO DE UN ANALOGO DE 1,3 EOSIDO Y DERIVADOS FARMACEUTICAMENTE ACEPTABLES DE EL PARA EL TRATAMIENTO DE INFECCIONES VIRICAS DE HEPATITIS B. TAMBIEN SE PROVEEN FORMULACIONES FARMACEUTICAS.
ES92906520T 1991-03-06 1992-03-05 Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b. Expired - Lifetime ES2179040T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919104741A GB9104741D0 (en) 1991-03-06 1991-03-06 Therapeutic nucleosides
GB919109505A GB9109505D0 (en) 1991-05-02 1991-05-02 Therapeutic nucleosides

Publications (1)

Publication Number Publication Date
ES2179040T3 true ES2179040T3 (es) 2003-01-16

Family

ID=26298535

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01202860T Expired - Lifetime ES2286072T3 (es) 1991-03-06 1992-03-05 Sales de amidas de (-)cis 5 fluoro-2'-dedoxi-3'-tiacitidina utiles para el tratamiento de la hepatitis b.
ES92906520T Expired - Lifetime ES2179040T3 (es) 1991-03-06 1992-03-05 Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES01202860T Expired - Lifetime ES2286072T3 (es) 1991-03-06 1992-03-05 Sales de amidas de (-)cis 5 fluoro-2'-dedoxi-3'-tiacitidina utiles para el tratamiento de la hepatitis b.

Country Status (21)

Country Link
EP (3) EP1808434A3 (es)
JP (5) JP3479068B2 (es)
KR (1) KR100270806B1 (es)
AT (2) ATE361293T1 (es)
AU (1) AU662130B2 (es)
CA (1) CA2105486C (es)
CZ (1) CZ282747B6 (es)
DE (2) DE69233693T2 (es)
DK (2) DK1142891T3 (es)
ES (2) ES2286072T3 (es)
HU (1) HUT64844A (es)
IE (1) IE920701A1 (es)
IL (1) IL101144A (es)
MX (1) MX9203213A (es)
NZ (1) NZ264621A (es)
PT (1) PT100198B (es)
RU (1) RU2116789C1 (es)
SK (1) SK279542B6 (es)
TW (1) TW201268B (es)
UA (1) UA54364C2 (es)
WO (1) WO1992015308A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226137B1 (en) * 1989-02-08 2008-05-28 Shire Canada Inc Process for preparing substituted 1,3-oxathiolanes with antiviral properties
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
RU2116789C1 (ru) * 1991-03-06 1998-08-10 Дзе Велкам Фаундейшн Лимитед Способ ингибирования вирусных инфекций гепатита в
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
DK0831852T3 (da) 1995-06-07 2007-03-19 Univ Emory Nukleosider med anti-hepatitis B-virusaktivitet
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
DE69823984T2 (de) 1997-03-19 2005-05-12 University Of Georgia Research Foundation, Inc. Synthese, anti-hiv- und anti-hepatitis-b-virus-aktivitäten von 1,3-oxaselenolannukleosiden
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
ATE313550T1 (de) 1998-08-10 2006-01-15 Idenix Cayman Ltd Beta-l-2'-deoxynukleoside für die behandlung von hepatitis b virus
EP1104415B1 (en) 1998-08-12 2004-11-10 Gilead Sciences, Inc. Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
RU2237479C2 (ru) * 1998-11-05 2004-10-10 Сантр Насьональ Де Ля Решерш Сьентифик Нуклеозиды, обладающие активностью против вируса гепатита в
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
EP1387850A2 (en) 2001-05-18 2004-02-11 Rakesh Kumar Antiviral nucleosides
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
DK1572095T3 (en) 2002-09-13 2015-09-14 Novartis Ag BETA-L-2'-DEOXYNUCLEOTIDES FOR TREATMENT OF RESISTANT HBV STANDS AND COMBINATION THERAPIES
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
CA2724740C (en) 2008-06-30 2017-02-21 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
WO2013004658A1 (en) * 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
WO1990014079A1 (en) 1989-05-15 1990-11-29 The United States Of America, Represented By The Secretary, United States Department Of Commerce Method of treatment of hepatitis
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
RU2116789C1 (ru) * 1991-03-06 1998-08-10 Дзе Велкам Фаундейшн Лимитед Способ ингибирования вирусных инфекций гепатита в

Also Published As

Publication number Publication date
CZ183593A3 (en) 1994-04-13
IE920701A1 (en) 1992-09-09
EP1808434A3 (en) 2008-04-02
JP3987335B2 (ja) 2007-10-10
PT100198A (pt) 1993-05-31
JP3479068B2 (ja) 2003-12-15
DK0574487T3 (da) 2002-10-14
JP2010013466A (ja) 2010-01-21
EP1142891B1 (en) 2007-05-02
AU1367692A (en) 1992-10-06
EP1808434A2 (en) 2007-07-18
CA2105486C (en) 2003-10-28
SK95093A3 (en) 1994-04-06
NZ264621A (en) 1997-09-22
HUT64844A (en) 1994-03-28
JP2007246536A (ja) 2007-09-27
RU2116789C1 (ru) 1998-08-10
UA54364C2 (uk) 2003-03-17
ES2286072T3 (es) 2007-12-01
IE20040402A1 (en) 2007-10-17
JPH06505725A (ja) 1994-06-30
JP4891435B2 (ja) 2012-03-07
IL101144A (en) 1996-09-12
DE69233693T2 (de) 2008-01-24
ATE361293T1 (de) 2007-05-15
EP0574487B1 (en) 2002-06-19
ATE219366T1 (de) 2002-07-15
JP2011102308A (ja) 2011-05-26
PT100198B (pt) 2000-03-31
DK1142891T3 (da) 2007-08-27
KR100270806B1 (ko) 2000-11-01
DE69232649D1 (de) 2002-07-25
WO1992015308A1 (en) 1992-09-17
IL101144A0 (en) 1992-11-15
DE69233693D1 (de) 2007-06-14
CZ282747B6 (cs) 1997-09-17
JP4399478B2 (ja) 2010-01-13
CA2105486A1 (en) 1992-09-07
DE69232649T2 (de) 2002-11-28
HU9302493D0 (en) 1993-11-29
AU662130B2 (en) 1995-08-24
TW201268B (es) 1993-03-01
SK279542B6 (sk) 1998-12-02
EP1142891A1 (en) 2001-10-10
EP0574487A1 (en) 1993-12-22
JP2002220388A (ja) 2002-08-09
MX9203213A (es) 1992-07-01

Similar Documents

Publication Publication Date Title
ES2179040T3 (es) Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.
ES2083668T5 (es) Combinaciones antiviricas que contienen analogos de nucleosido.
DK0574457T3 (da) Antiviral nucleosidkombination
MX9205046A (es) 1h-imidazo-(4,5-c)quinolin-4-aminas 1-substituidas
ES2186667T3 (es) Analogos de nucleosidos de 1,3-oxatiolano.
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
NL300136I2 (nl) Farmacologisch actieve catecholderivaten en samenstellingen ervan.
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
MX9200361A (es) Nuevo uso del antagonista de adenosina.
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
ES2051754T3 (es) Uso de derivados cetonicos en el tratamiento de la depresion.
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
ES2059534T3 (es) Nuevos derivados benzopiranos antihipertensivos.
GR1001511B (el) Στεροειδείς συν?έσεις.
TR27833A (tr) Antelmintik'lerin uygulanmasina mahsus ''pour-on'' formülasyonu.
MY137298A (en) Therapeutic nucleosides
TR199900013T2 (xx) Yeni bile�ikler.
BR9106372A (pt) Derivados 1,5-benzotiazepinona,suas preparacoes e uso farmaceutico
SE9602262D0 (sv) New use of derivatives of cystine
ES2150034T3 (es) Empleo de las 2-aminotetralinas substituidas en 6,7 para la preparacion de composiciones farmaceuticas de utilidad para el tratamiento del choque septico, y composiciones farmaceuticas antipireticas y antiinflamatorias.
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
MY113560A (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b
ES2169116T3 (es) Uso de los derivados de 2-amino purina en el tratamiento y profilaxis del virus 6 del herpes humano.
ITRM920930A1 (it) Impiego del glutatione per la preparazione di composizioni farmaceutiche ad attivita' antivirale.
MX9203485A (es) Derivados de tieno sulfonamida, composiciones farmaceuticas y uso.